The Indication of Palliative Whole-brain Radiotherapy for Patients with Brain Metastases: a Simple Prognostic Scoring System in the Era of Stereotactic Radiosurgery

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 Aug 2

PMID 39095756

Authors

Toshiaki Hirose

Shoichi Deguchi

Kazuaki Yasui

Minoru Inoue

Tsuyoshi Onoe

Hirofumi Ogawa

Hirofumi Asakura

Koichi Mitsuya

Hideyuki Harada

Shigeyuki Murayama

Nakamasa Hayashi

Tetsuo Nishimura

Ryuta Saito

Affiliations

Soon will be listed here.

Abstract

Background: Stereotactic irradiation has become the mainstay treatment for brain metastases (BM), and whole-brain radiotherapy (WBRT) is often used for symptom palliation. However, the survival time of patients with BM undergoing palliative WBRT (pWBRT) is limited, making it difficult to select patients who should receive treatment.

Methods: We collected patient data from 2016 to 2022 at the Shizuoka Cancer Center and retrospectively analyzed the factors related to survival time. Overall survival (OS) was defined as the survival time after WBRT.

Results: A total of 301 patients (median age, 66 years) who underwent pWBRT were included. The primary cancers were lung, breast, gastrointestinal tract, and other cancers in 203 (67%), 38 (13%), 33 (11%), and 27 (9%) patients, respectively. Median OS of all patients was 4.1 months. In the multivariate analysis, male sex (hazard ratio [HR]:1.4), Karnofsky Performance Status (KPS) ≤ 60 (HR:1.7), presence of extracranial metastasis (ECM) (HR:1.6), neutrophil-lymphocyte ratio (NLR) ≥ 5 (HR:1.6), and lactate dehydrogenase (LDH) ≥ upper limit of normal (ULN) (HR:1.3) were significantly associated with shorter OS (all P < 0.05). To predict the OS, we created a prognostic scoring system (PSS). We gave one point to each independent prognostic factor. Median OS for patients with scores of 0-2, 3, and 4-5 were 9.0, 3.5 and 1.7 months, respectively (P < 0.001).

Conclusions: Male sex, KPS ≤ 60, presence of ECM, NLR ≥ 5, and LDH ≥ ULN were poor prognostic factors for patients with BM undergoing pWBRT. By PSS combining these factors, it may be possible to select patients who should undergo pWBRT.

References

Sperduto P, Berkey B, Gaspar L, Mehta M, Curran W . A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2007; 70(2):510-4. DOI: 10.1016/j.ijrobp.2007.06.074. View

Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T . Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997; 37(4):745-51. DOI: 10.1016/s0360-3016(96)00619-0. View

Doi H, Nakamatsu K, Anami S, Fukuda K, Inada M, Tatebe H . Neutrophil-to-Lymphocyte Ratio Predicts Survival After Whole-brain Radiotherapy in Non-small Cell Lung Cancer. In Vivo. 2018; 33(1):195-201. PMC: 6364074. DOI: 10.21873/invivo.11459. View

Mitsuya K, Nakasu Y, Kurakane T, Hayashi N, Harada H, Nozaki K . Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of worse survival after resection in patients with brain metastasis. J Neurosurg. 2016; 127(2):433-437. DOI: 10.3171/2016.8.JNS16899. View

Berghoff A, Wolpert F, Holland-Letz T, Koller R, Widhalm G, Gatterbauer B . Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score. Neuro Oncol. 2017; 19(9):1255-1262. PMC: 5570252. DOI: 10.1093/neuonc/now290. View

Kondziolka D, Parry P, Lunsford L, Kano H, Flickinger J, Rakfal S . The accuracy of predicting survival in individual patients with cancer. J Neurosurg. 2013; 120(1):24-30. DOI: 10.3171/2013.9.JNS13788. View

Hui C, Qu V, Wang J, von Eyben R, Chang Y, Chiang P . Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer. J Neurooncol. 2022; 160(1):233-240. DOI: 10.1007/s11060-022-04145-x. View

Nussbaum E, Djalilian H, Cho K, Hall W . Brain metastases. Histology, multiplicity, surgery, and survival. Cancer. 1996; 78(8):1781-8. View

Pirovano M, Maltoni M, Nanni O, Marinari M, Indelli M, Zaninetta G . A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. J Pain Symptom Manage. 1999; 17(4):231-9. DOI: 10.1016/s0885-3924(98)00145-6. View

10.

Wakuda K, Yabe M, Kodama H, Nishioka N, Miyawaki T, Miyawaki E . Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression. Lung Cancer. 2020; 151:60-68. DOI: 10.1016/j.lungcan.2020.11.009. View

11.

Harada H, Asakura H, Ogawa H, Mori K, Takahashi T, Nakasu Y . Prognostic factors in patients with brain metastasis from non-small cell lung cancer treated with whole-brain radiotherapy. J Cancer Res Ther. 2016; 12(1):267-70. DOI: 10.4103/0973-1482.167610. View

12.

Nagai N, Koide Y, Shindo Y, Hashimoto S, Tachibana H, Kodaira T . Retrospective non-inferiority study of stereotactic radiosurgery for more than ten brain metastases. J Neurooncol. 2023; 163(2):385-395. DOI: 10.1007/s11060-023-04358-8. View

13.

Cho A, Untersteiner H, Fitschek F, Khalaveh F, Pruckner P, Pavo N . The clinical relevance of laboratory prognostic scores for patients with radiosurgically treated brain metastases of non-pulmonary primary tumor. J Neurooncol. 2021; 153(3):497-505. PMC: 8279966. DOI: 10.1007/s11060-021-03788-6. View

14.

Keit E, Lee S, Woodward M, Rembielak A, Shiue K, Desideri I . Palliative whole brain radiation therapy: an international state of practice. Ann Palliat Med. 2023; 12(6):1155-1164. DOI: 10.21037/apm-23-448. View

15.

Suh J, Kotecha R, Chao S, Ahluwalia M, Sahgal A, Chang E . Current approaches to the management of brain metastases. Nat Rev Clin Oncol. 2020; 17(5):279-299. DOI: 10.1038/s41571-019-0320-3. View

16.

Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J . Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014; 15(4):387-95. DOI: 10.1016/S1470-2045(14)70061-0. View

17.

Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2012; 48(3):452-8. PMC: 3590441. DOI: 10.1038/bmt.2012.244. View

18.

Flores-Paco P, Vargas-Aliaga A, Guevara M, Lopera I, Ruiz L, Lopez-Herrero M . A new updated prognostic index for patients with brain metastases (BMs) treated with palliative whole brain radiotherapy (WBRT) in the era of precision oncology. METASNCore project. J Neurooncol. 2024; 167(3):407-413. DOI: 10.1007/s11060-024-04618-1. View

19.

Adegboyega B, Joseph A, Alabi A, Omomila J, Ngema L, Ainsworth V . Patient reported outcomes following whole brain radiotherapy in patients with brain metastases in NSIA-LUTH Cancer Center. BMC Cancer. 2023; 23(1):1233. PMC: 10722749. DOI: 10.1186/s12885-023-11675-8. View

20.

Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E . Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3,.... Lancet. 2016; 388(10055):2004-2014. PMC: 5082599. DOI: 10.1016/S0140-6736(16)30825-X. View